

**Supplementary Table 2** Treatment-emergent adverse events regardless of relation to study drug leading to permanent treatment discontinuation

n (%)	Regorafenib (N=100)		
	Grade 3	Grade 4	Any grade
Any TEAE leading to permanent discontinuation <sup>a</sup>	15 (15)	6 (6)	28 (28)
Blood bilirubin increased	6 (6)	0	10 (10)
AST increased	4 (4)	0	6 (6)
ALT increased	4 (4)	0	5 (5)
Alkaline phosphatase increased	2 (2)	0	3 (3)
Diarrhea	2 (2)	0	2 (2)
Hepatic failure	2 (2)	0	2 (2)
Hypophosphatemia	2 (2)	0	2 (2)
Lipase increased	0	2 (2)	2 (2)
Lung infection	1 (1)	0	2 (2)

Events and grades by CTCAE v4.0.

<sup>a</sup>Individual events listed are those occurring in  $\geq 2\%$  of patients.

ALT=alanine aminotransferase; AST=aspartate aminotransferase; CTCAE=Common Terminology Criteria for Adverse Events; TEAE=treatment-emergent adverse event.